For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Alnylam Pharmaceuticals Inc’s stock clocked out at $451.23, up 1.37% from its previous closing price of $445.12. In other words, the price has increased by $1.37 from its previous closing price. On the day, 0.56 million shares were traded. ALNY stock price reached its highest trading level at $455.755 during the session, while it also had its lowest trading level at $444.43.
Ratios:
To gain a deeper understanding of ALNY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 269.31. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when Fitzgerald Kevin Joseph sold 12,128 shares for $452.18 per share. The transaction valued at 5,483,990 led to the insider holds 21,264 shares of the business.
Fitzgerald Kevin Joseph bought 12,128 shares of ALNY for $5,445,472 on Nov 17 ’25. On Nov 12 ’25, another insider, Greenstreet Yvonne, who serves as the Chief Executive Officer of the company, sold 15,650 shares for $453.69 each. As a result, the insider received 7,100,322 and left with 65,409 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 59613720576 and an Enterprise Value of 59662401536. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1877.00, and their Forward P/E ratio for the next fiscal year is 59.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.57 while its Price-to-Book (P/B) ratio in mrq is 254.25. Its current Enterprise Value per Revenue stands at 18.586 whereas that against EBITDA is 185.852.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.30, which has changed by 0.78344727 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -1.05%, while the 200-Day Moving Average is calculated to be 28.01%.
Shares Statistics:
It appears that ALNY traded 1.09M shares on average per day over the past three months and 981030 shares per day over the past ten days. A total of 131.79M shares are outstanding, with a floating share count of 129.75M. Insiders hold about 1.79% of the company’s shares, while institutions hold 99.34% stake in the company. Shares short for ALNY as of 1763078400 were 4279250 with a Short Ratio of 3.94, compared to 1760486400 on 3993922. Therefore, it implies a Short% of Shares Outstanding of 4279250 and a Short% of Float of 4.2600001999999995.
Earnings Estimates
Currently, 11.0 analysts are dedicated to thoroughly evaluating and rating the performance of Alnylam Pharmaceuticals Inc (ALNY) in the stock market.The consensus estimate for the next quarter is $2.09, with high estimates of $2.55 and low estimates of $1.55.
Analysts are recommending an EPS of between $5.99 and $3.76 for the fiscal current year, implying an average EPS of $4.96. EPS for the following year is $10.61, with 12.0 analysts recommending between $13.86 and $6.44.
Revenue Estimates
In . The current quarter, 20 analysts expect revenue to total $1.17B. It ranges from a high estimate of $1.61B to a low estimate of $1.04B. As of . The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 20 analysts are estimating revenue of $1.22B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 25 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.42B, resulting in an average revenue estimate of $3.74B. In the same quarter a year ago, actual revenue was $2.25BBased on 24 analysts’ estimates, the company’s revenue will be $5.35B in the next fiscal year. The high estimate is $6.12B and the low estimate is $4.34B.
